Leo Pharma not as affected by pricing pressure as Novo
While Novo Nordisk has been hit by an increased pressure on prices in the US, Leo Pharma is not as affected by the new reality on the world’s biggest drug market to the same extent. But growth will not come through price hikes, says CEO Gitte Aabo.
BY STEFAN SINGH KAILAY
After years of feeling the heat on its business in the US, 2016 looks like the year when growth returns to Leo Pharma’s operations across the Atlantic.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo CEO: New arena requires new skills
For abonnenter
Leo Pharma makes managerial changes
For abonnenter
Rival to follow Leo Pharma into biologics segment
For abonnenter
